

# TASMAR\* (tolcapone)

\* Prior authorization for the brand formulation applies only to formulary exceptions due to being a non-covered medication.

### **Pre - PA Allowance**

None

## **Prior-Approval Requirements**

**Age** 18 years of age or older

**Diagnosis** 

Patient must have the following:

Parkinson's disease

#### AND ALL of the following:

- 1. Used in combination with carbidopa/levodopa
- 2. Inadequate control of Parkinson's symptoms on maximum tolerated doses of oral carbidopa/levodopa therapy
- 3. Inadequate response, intolerance, or contraindication to other adjunctive therapy
- 4. Prescriber agrees to monitor for liver failure/hepatic dysfunction
- Prescriber agrees to discontinue Tasmar (tolcapone) if ALT or AST levels exceed 2 times the upper limit of normal

## **Prior - Approval Limits**

### Quantity

Drug	Quantity
Tolcapone	270 tablets per 90 days

Drug with approved MFE only	Quantity
Tasmar	270 tablets per 90 days

**Duration** 6 months

## Prior - Approval Renewal Requirements

Age 18 years of age or older



## TASMAR\* (tolcapone)

\* Prior authorization for the brand formulation applies only to formulary exceptions due to being a non-covered medication.

#### **Diagnosis**

Patient must have the following:

Parkinson's disease

#### AND ALL of the following:

- 1. Improvement in Parkinson's symptoms
- 2. Used in combination with carbidopa/levodopa
- 3. Prescriber agrees to monitor for liver failure/hepatic dysfunction
- 4. Prescriber agrees to discontinue Tasmar (tolcapone) if ALT or AST levels exceed 2 times the upper limit of normal

## Prior - Approval Renewal Limits

#### Quantity

Drug	Quantity
Tolcapone	270 tablets per 90 days

Drug with approved MFE only	Quantity
Tasmar	270 tablets per 90 days

**Duration** 12 months